Lung cancer screening with low dose CT requires careful consideration

Zaigham Saghir, Haseem Ashraf, Karen Skjøldstrup Bach, John Brodersen, Paul Frost Clementsen, Martin Døssing, Hanne Hansen, Klaus Fuglsang Kofoed, Klaus Richter Larsen, Jann Mortensen, Jakob Fraes Rasmussen, Laura Hohwü Thomsen, Mathilde Marie Winkler Wille, Niels Seersholm, Birgit Guldhammer Skov, Hanne Thorsen, Philip Tønnesen, Jesper Holst Pedersen

Publikation: Bidrag til tidsskriftReviewForskningpeer review

1 Citationer (Scopus)

Abstract

Results from the American National Lung Screening Trial (NLST) show a significant reduction in lung cancer and all-cause mortality in a high risk population screened with annual low-dose CT. Handling of pulmonary nodules, false positive tests, overdiagnosis, psychosocial consequences and cost-efficiency etc. are all aspects that require careful consideration. This paper gives an overview of the current knowledge on these issues. Before a recommendation can be made, we need an overall evaluation of both the benefits and harms in CT screening for lung cancer.

OriginalsprogEngelsk
TidsskriftUgeskrift for Laeger
Vol/bind176
Udgave nummer42
ISSN0041-5782
StatusUdgivet - 13 okt. 2014

Citationsformater